Zydus Cadila gets USFDA’s nod to initiate clinical trials of Desidustat in CIA

23 Jul 2020 Evaluate

Zydus Cadila has received approval from US Food and Drug Administration (USFDA) to initiate clinical trials of Desidustat in Chemotherapy Induced Anemia (CIA). Desidustat is expected to increase the red blood cell count and restore the erythropoietin levels to the normal levels in the cancer patients with CIA. Estimates suggest approximately 1.3 million cancer patients undergo chemotherapy every year in the United States and 30% to 90% of cancer patients receiving chemotherapy develop anemia.

Desidustat is a novel, oral, hypoxia inducible factor prolyl hydroxylase inhibitor, currently undergoing Phase 3 trials for treating anemia in Chronic Kidney Disease Patients. Zydus had initiated two Phase III trials of Desidustat. Zydus has also initiated a Phase II (b) trial of Desidustat in Mexico for the management of patients with COVID-19.

Cadila Healthcare is an India-based pharmaceutical company. The company's subsidiaries include Zydus Wellness, Liva Pharmaceuticals, Biochem Pharmaceutical Industries, Zydus Technologies, German Remedies, Dialforhealth India, Dialforhealth Unity and Dialforhealth Greencross, among others.

Zydus Lifesciences Share Price

956.30 -3.15 (-0.33%)
23-Apr-2024 13:55 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1493.25
Dr. Reddys Lab 5992.55
Cipla 1363.80
Zydus Lifesciences 956.30
Lupin 1587.40
View more..
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt.Ltd.